[Urinary excretion of mutagens and cisplatin among the nursing staff at a medical oncology department exposed to cytostatic drugs]
- PMID: 2622413
[Urinary excretion of mutagens and cisplatin among the nursing staff at a medical oncology department exposed to cytostatic drugs]
Abstract
Exposure to cytostatic drugs was assessed in a group of 9 nurses employed in a hospital cancer therapy department by measuring the post-shift levels of urinary mutagens and cis-platinum. A slight but significant increase in urinary mutagenic activity compared to 11 controls was observed in the non-smokers: the mean values of mutagenic activity on the Ta100 strain in the presence of both microsomal and deconjugating enzymes were 4418 +/- 1186 and 2468 +/- 1681 respectively. Conversely, the urinary platinum concentration was below the detection limit of the analytical method (10 micrograms/l) in all samples. The increased urinary mutagenic activity in the exposed group can probably be attributed to the absorption of cyclophosphamide either during preparation and administration of the drug, or due to accidental contact with contaminated biological fluids, in view of the fact that the level of mutagens in urine samples from cyclophosphamide-treated patients is extremely high (up to 319,478 revertants/g creatinine in the case we examined).
Similar articles
-
Limitations of the salmonella/mammalian microsome assay (Ames test) to determine occupational exposure to cytostatic drugs.Eur J Cancer Clin Oncol. 1986 May;22(5):567-75. doi: 10.1016/0277-5379(86)90045-3. Eur J Cancer Clin Oncol. 1986. PMID: 3533554
-
Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs.Am J Hosp Pharm. 1986 Feb;43(2):344-8. Am J Hosp Pharm. 1986. PMID: 3513557
-
Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures.Cancer Res. 1985 Dec;45(12 Pt 1):6487-97. Cancer Res. 1985. PMID: 4063994
-
Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs.Mutagenesis. 2007 Nov;22(6):395-401. doi: 10.1093/mutage/gem032. Epub 2007 Sep 13. Mutagenesis. 2007. PMID: 17855733
-
Monitoring of occupational exposure to cytostatic anticancer agents.Mutat Res. 1996 Aug 17;355(1-2):253-61. doi: 10.1016/0027-5107(96)00031-0. Mutat Res. 1996. PMID: 8781586 Review.